137 related articles for article (PubMed ID: 30391119)
21. Palliative and supportive care for glioma patients.
Walbert T; Chasteen K
Cancer Treat Res; 2015; 163():171-84. PubMed ID: 25468232
[TBL] [Abstract][Full Text] [Related]
22. Surgical assessment of the insula. Part 2: validation of the Berger-Sanai zone classification system for predicting extent of glioma resection.
Hervey-Jumper SL; Li J; Osorio JA; Lau D; Molinaro AM; Benet A; Berger MS
J Neurosurg; 2016 Feb; 124(2):482-8. PubMed ID: 26339856
[TBL] [Abstract][Full Text] [Related]
23. Low Grade Gliomas in Children.
Chalil A; Ramaswamy V
J Child Neurol; 2016 Mar; 31(4):517-22. PubMed ID: 26286938
[TBL] [Abstract][Full Text] [Related]
24. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
25. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
26. [An evidence based strategy for WHO Grade II Gliomas].
Narita Y
No Shinkei Geka; 2013 Jul; 41(7):565-81. PubMed ID: 23824347
[No Abstract] [Full Text] [Related]
27. Contemporary management of low--grade glioma: a paradigm shift in neuro-oncology.
Hayhurst C
Pract Neurol; 2017 Jun; 17(3):183-190. PubMed ID: 28315827
[TBL] [Abstract][Full Text] [Related]
28. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
Agnihotri S; Aldape KD; Zadeh G
Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
[TBL] [Abstract][Full Text] [Related]
29. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
de la Fuente MI; Young RJ; Rubel J; Rosenblum M; Tisnado J; Briggs S; Arevalo-Perez J; Cross JR; Campos C; Straley K; Zhu D; Dong C; Thomas A; Omuro AA; Nolan CP; Pentsova E; Kaley TJ; Oh JH; Noeske R; Maher E; Choi C; Gutin PH; Holodny AI; Yen K; DeAngelis LM; Mellinghoff IK; Thakur SB
Neuro Oncol; 2016 Feb; 18(2):283-90. PubMed ID: 26691210
[TBL] [Abstract][Full Text] [Related]
30. Implementation of Tobacco Dependence Treatment Programs in Oncology Settings.
Sarna L; Bialous SA
Semin Oncol Nurs; 2016 Aug; 32(3):187-96. PubMed ID: 27539275
[TBL] [Abstract][Full Text] [Related]
31. Update in the treatment of high-grade Gliomas.
Lukas RV; Nicholas MK
Neurol Clin; 2013 Aug; 31(3):847-67. PubMed ID: 23896509
[TBL] [Abstract][Full Text] [Related]
32. Further understanding of the pathology of glioma: implications for the clinic.
Camelo-Piragua S; Kesari S
Expert Rev Neurother; 2016 Sep; 16(9):1055-65. PubMed ID: 27228211
[TBL] [Abstract][Full Text] [Related]
33. Updated response assessment criteria for high-grade glioma: beyond the MacDonald criteria.
Sharma M; Juthani RG; Vogelbaum MA
Chin Clin Oncol; 2017 Aug; 6(4):37. PubMed ID: 28841799
[TBL] [Abstract][Full Text] [Related]
34. The Role of Survivorship Care for Patients with Glioma.
Brown CB; Leeper HE
Semin Oncol Nurs; 2018 Dec; 34(5):547-552. PubMed ID: 30446382
[TBL] [Abstract][Full Text] [Related]
35. Low-grade glioma.
Kumthekar P; Raizer J; Singh S
Cancer Treat Res; 2015; 163():75-87. PubMed ID: 25468226
[TBL] [Abstract][Full Text] [Related]
36. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
Michotte A; Neyns B; Chaskis C; Sadones J; In 't Veld P
Acta Neurol Belg; 2004 Dec; 104(4):148-53. PubMed ID: 15742604
[TBL] [Abstract][Full Text] [Related]
37. FGF2 as a potential prognostic biomarker for proneural glioma patients.
Sooman L; Freyhult E; Jaiswal A; Navani S; Edqvist PH; Pontén F; Tchougounova E; Smits A; Elsir T; Gullbo J; Lennartsson J; Bergqvist M; Ekman S
Acta Oncol; 2015 Mar; 54(3):385-94. PubMed ID: 25263081
[TBL] [Abstract][Full Text] [Related]
38. [Standards, Options and Recommendations 2002 for the management of adult patients with intracranial gliomas (summary report)].
Frappaz D; Chinot O; Bataillard A; Ben Hassel M; Capelle L; Chanalet S; Chatel M; Figarella-Branger D; Guegan Y; Guyotat J; Khé HX; Jouanneau E; Keime-Guibert F; Laforêt C; Linassier C; Loiseau H; Menel P; Rousmans S; Sanson M; Sunyach MP
Bull Cancer; 2003 Oct; 90(10):873-86. PubMed ID: 14706916
[TBL] [Abstract][Full Text] [Related]
39. Low-grade gliomas: clinical and pathobiological aspects.
Smits A
Histol Histopathol; 2002 Jan; 17(1):253-60. PubMed ID: 11813876
[TBL] [Abstract][Full Text] [Related]
40. IDH1 status is significantly different between high-grade thalamic and superficial gliomas.
Zuo M; Li M; Chen N; Yu T; Kong B; Liang R; Wang X; Mao Q; Liu Y
Cancer Biomark; 2017 Aug; 20(2):183-189. PubMed ID: 28869450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
